MEN1703 clinical trials

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

This study looks at a new drug, MEN1703, alone or with another drug, glofitamab, for people with a type of aggressive non-Hodgkin lymphoma that has returned or hasn't responded to other treatments. It aims to see if these treatments are safe and help shrink the lymphoma.